Novo Nordisk will soon announce the results of perhaps the most ambitious studies yet of its GLP-1 drug: whether it can help ...

For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably ...

Lower prices for 15 drugs, including Ozempic and Wegovy, are expected to be announced by the end of the month. The price ...

A new generation of companies is eyeing the existing, sizeable hair loss market, hoping that better formulations and new ...

Unprecedented surge in Irish exports this year was almost entirely driven by shipments of drug ingredients for Eli Lilly ...

The clock is up on Biogen’s extra two years of a biosimilar-free U.S. market for its blockbuster multiple sclerosis (MS) med ...

Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in the space.

Profluent has raised $106 million to scale up use of its AI models for biology in drug development and agriculture.

Shares jumped after Wedbush raised its target and B. Riley initiated coverage, pointing to strong early launch momentum for ...

Regeneron Pharmaceuticals has won expanded European approval of its blockbuster cancer drug Libtayo for certain patients with skin cancer. Regeneron on Wednesday said the European Commission's nod ...

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of ...